In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia Cheel (tea tree) oil against azole-susceptible and -resistant human pathogenic Candida species

BMC Infectious Diseases

Volumn 6, Issue , 2006, Pages

  Mondello, Francesca ^a   De Bernardis, Flavia ^a   Girolamo, Antonietta ^a   Cassone, Antonio ^a   Salvatore, Giuseppe ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CINEOLE; ESTROGEN; FLUCONAZOLE; ITRACONAZOLE; PYRROLE DERIVATIVE; TEA TREE OIL; TERPINEN 4 OL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DATA ANALYSIS; DILUTION; DRUG SENSITIVITY; ESTROGEN THERAPY; FEMALE; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OVARIECTOMY; RAT; VAGINA CANDIDIASIS;

ANIMALS; ANTIFUNGAL AGENTS; AZOLES; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS, VULVOVAGINAL; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HUMANS; MELALEUCA; MICROBIAL SENSITIVITY TESTS; RATS; TEA TREE OIL; TERPENES; TREATMENT OUTCOME;

EID: 33751341585     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-6-158     Document Type: Article

References (26)

1. Martin KW, Ernst E: Herbal medicines for treatment of fungal infections: a systematic review of controlled clinical trials. Mycoses 2004, 47:87-92.
2. Calcabrini A, Stringaro A, Toccacieli L, Meschini S, Marra M, Colone M, Salvatore G, Mondello F, Arancia G, Molinari A: Terpinen-4-ol, the main component of Melaleuca alternifolia (tea tree) oil inhibits the in vitro growth of human melanoma cells. J Invest Dermatol 2004, 122:349-360.
3. Arweiler NB, Donos N, Netuschil L, Reich E, Sculean A: Clinical and antibacterial effect of tea tree oils: a pilot study. Clin Oral Investig 2000, 4:70-73.
4. European Directorate for the Quality of Medicines: The 5th Edition of European Pharmacopoeia and its subsequent supplements. [5.5 CD-Rom 07/ 2006]
5. International Organization for Standardization. ISO 4730: Oil of Melaleuca, Terpinen-4-ol type (Tea Tree Oil) Geneva: International Organization for Standardization; 1996.
6. Cox SD, Mann CM, Markham JL: Interactions between components of the essential oil of Melaleuca alternifolia. J Appl Microbiol 2001, 91:492-497.
7. Hart PH, Brand C, Carson CF, Ryley TV, Prager RH, Finlay-Jones JJ: Terpinen-4-ol, the main component of the essential oil of Melaleuca alternifolia (tea tree oil), suppresses inflammatory mediator production by activated human monocytes. Inflamm Res 2000, 49:619-626.
8. Carson CF, Riley TV: Safety, efficacy and provenance of tea tree (Melaleuca alternifolia) oil. Contact Dermatitis 2001, 45:65-67.
9. Sobel JD: Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 1992, 14:148-153.
10. Mondello F, De Bernardis F, Girolamo A, Salvatore G, Cassone A: In vitro and in vivo activity of tea tree oil against azole-susceptible and -resistant human pathogenic yeasts. J Antimicrob Chemother 2003, 51:1223-1229.
11. National Committee for Clinical Laboratory Standards: Reference Method for broth dilution antifungal susceptibility testing of yeasts: Approved Standard M27-A2 NCCLS, Villanova, PA, USA; 2002.
12. Meyer SA, Ahearn DG, Yarrow D: Genus 4. Candida Berkhout. In Kreger-van Rij NJW. The Yeasts: A Taxonomic Study Elsevier Science. Amsterdam; 1984:585-844.
13. Hammer KA, Carson CF, Riley TV: In vitro activity of essential oils, in particular Melaleuca alternifolia (tea tree) oil and tea tree products, against Candida spp. J Antimicrob Chemother 1998, 42:591-595.
14. De Bernardis F, Lorenzini R, Cassone A: Rat model of Candida vaginal infection. In Handbook of Animal Models of Infection New York: Academic Press; 1999:735-740.
15. Adams RP: Identification of essential oil components by gas chromatography/mass spectroscopy Allured Publishing Corporation. Carol Stream, Illinois; 1995.
16. Carson CF, Hammer KA, Riley TV: Melaleuca alternifolia (Tea Tree) oil: a review of antimicrobial and other medicinal properties. Clin Microbiol Rev 2006, 19:50-62.
17. Hammer KA, Carson CF, Riley TV: Antifungal activity of the components of Melaleuca alternifolia (tea tree) oil. J Appl Microbiol 2003, 95:853-860.
18. D'Auria F, Laino L, Strippoli V, Tecca M, Salvatore G, Battinelli L, Mazzanti G: In vitro activity of Tea Tree Oil against Candida albicans mycelial conversion and other pathogenic fungi. J Chemother 2001, 13:377-383.
19. Cox SD, Mann CM, Markham JL: Interactions between components of the essential oil of Melaleuca alternifolia. J Appl Microbiol 2001, 91:492-497.
20. Oliva B, Piccirilli E, Ceddia T, Pontieri E, Aureli P, Ferrini AM: Antimycotic activity of Melaleuca alternifolia essential oil and its major components. Lett Appl Microbiol 2003, 37:185-187.
21. May J, Chan CH, King A, Williams L, French GL: Time kill-studies of tea tree oils on clinical isolates. J Antimicrob Chemother 2000, 45:639-643.
22. Girmenia C, Tuccinardi C, Santilli S, Mondello F, Monaco M, Cassone A, Martino P: In vitro activity of fluconazole and voriconazole against isolates of Candida albicans from patients with haematological malignancies. J Antimicrob Chemother 2000, 46:479-483.
23. De Bernardis F, Boccanera M, Adriani D, Spreghini E, Santoni G, Cassone A: Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun 1997, 65:3399-3405.
24. De Bernardis F, Santoni G, Boccanera M, Spreghini E, Adriani D, Morelli L, Cassone A: Local anticandidal immune responses in a rat model of vaginal infection by and protection against Candida albicans. Infect Immun 2000, 68:3297-3304.
25. Man Y, Morrison PP, Cutler JE: A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun 1998, 66:5771-5776.
26. Cassone A, Cauda R: HIV proteinase inhibitors: do they really work against Candida in a clinical setting? Trends Microbiol 2002, 10:177-178.